Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis

Ahmed M. , Kundu G.C. , Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells, Mol Cancer 9 (2010), 101.

Ahmed M. , Behera R. , Chakraborty G. , Jain S. , Kumar V. , Sharma P. , Bulbule A. , Kale S. , Kumar S. , Mishra R. , Raja R. , Saraswati S. , Kaur R. , Soundararajan G. , Kumar D. , Thorat D. , Sanyal M. , Ramdasi A. , Ghosh P. , Kundu G.C. , Osteopontin: a potentially important therapeutic target in cancer, Expert Opin Ther Targets 15 (2011), 1113-1126.

Agrawal D. , Chen T. , Irby R. , Quackenbush J. , Chambers A.F. , Szabo M. , Cantor A. , Coppola D. , Yeatman T.J. , Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling, J Natl Cancer Inst 94 (2002), 513-521.

Ballehaninna U.K. , Chamberlain R.S. , Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9, Tumor Biol 34 (2013), 3279-3292.

Berezin A.E. , Kremzer A.A. , Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease, Atherosclerosis 229 (2013), 475-481.

Berrington de Gonzalez A. , Sweetland S. , Spencer E. , A meta-analysis of obesity and the risk of pancreatic cancer, Br J Cancer 89 (2003), 519-523.

Bertino G. , Ardiri A. , Malaguarnera M. , Malaguarnera G. , Bertino N. , Calvagno G.S. , Hepatocellualar carcinoma serum markers, Semin Oncol 39 (2012), 410-433.

Blogowski W. , Dolegowska K. , Deskur A. , Dolegowska B. , Starzyńska T. , An Attempt to Evaluate Selected Aspects of Bone-Fat Axis Function in Healthy Individuals and Patients With Pancreatic Cancer, Medicine (Baltimore) 94 (2015), e1303.

Brand R.E. , Nolen B.M. , Zeh H.J. , Allen P.J. , Eloubeidi M.A. , Goldberg M. , Elton E. , Arnoletti J.P. , Christein J.D. , Vickers S.M. , Langmead C.J. , Landsittel D.P. , Whitcomb D.C. , Grizzle W.E. , Lokshin A.E. , Serum biomarker panels for the detection of pancreatic cancer, Clin Cancer Res 17 (2010), 805-816.

Brott D.A. , Furlong S.T. , Adler S.H. , Hainer J.W. , Arani R.B. , Pinches M. , Rossing P. , Chaturvedi N. , DIRECT programme steering committee, characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes, Drug Des Devel Ther 9 (2015), 3191-3198.

Chambers A.F. , Wilson S.M. , Kerkvliet N. , O'Malley F.P. , Harris J.F. , Casson A.G. , Osteopontin expression in lung cancer, Lung Cancer 15 (1996), 311-323.

Chen J. , Singh K. , Mukherjee B.B. , Sodek J. , Developmental expression of osteopontin (OPN) mRNA in rat tissues: evidence for a role for OPN in bone formation and resorption, Matrix 13 (1993), 113-123.

Chen R. , Crispin D.A. , Pan S. , Hawley S. , McIntosh M.W. , May D. , Anton-Culver H. , Ziogas A. , Bronner M.P. , Brentnall T.A. , Pilot study of blood biomarker candidates for detection of pancreatic cancer, Pancreas 39 (2010), 981-988.

Collins A.L. , Rock J. , Malhotra L. , Frankel W.L. , Bloomston M. , Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma, Ann Surg Oncol 19 (2012), 2673-2678.

Coppola D. , Szabo M. , Boulware D. , Muraca P. , Alsarraj M. , Chambers A.F. , Yeatman T.J. , Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies, Clin Cancer Res 10 (2004), 184-190.

Dalamaga M. , Diakopoulos K.N. , Mantzoros C.S. , The role of adiponectin in cancer: a review of current evidence, Endocr Rev 33 (2012), 547-594.

Daniele G. , Guardado Mendoza R. , Winnier D. , Fiorentino T.V. , Pengou Z. , Cornell J. , Andreozzi F. , Jenkinson C. , Cersosimo E. , Federici M. , Tripathy D. , Folli F. , The inflammatory status score including IL-6, TNF-α , osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus, Acta Diabetol 51 (2014), 123-131.

Everhart J. , Wright D. , Diabetes mellitus as a risk factor for pancreatic cancer, A meta-analysis, JAMA 273 (1995), 1605-1609.

Fedarko N.S. , Jain A. , Karadag A. , Van Eman M.R. , Fisher L.W. , Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer, Clin Cancer Res 7 (2001), 4060-4066.

Freelove R. , Walling A.D. , Pancreatic cancer: diagnosis and management, Am Fam Phys 73 (2006), 485-492.

Fuchs C.S. , Colditz G.A. , Stampfer M.J. , Giovannucci E.L. , Hunter D.J. , Rimm E.B. , Willett W.C. , Speizer F.E. , A prospective study of cigarette smoking and the risk of pancreatic cancer, Arch Intern Med 156 (1996), 2255-2260.

Fukushima N. , Koopmann J. , Sato N. , Prasad N. , Carvalho R. , Leach S.D. , Hruban R.H. , Goggins M. , Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma, Mol Pathol 18 (2005), 779-787.

Genuth S. , Alberti K.G. , Bennett P. , Buse J. , Defronzo R. , Kahn R. , Kitzmiller J. , Knowler W.C. , Lebovitz H. , Lernmark A. , Nathan D. , Palmer J. , Rizza R. , Saudek C. , Shaw J. , Steffes M. , Stern M. , Tuomilehto J. , Zimmet P. , Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus, Diabetes Care 26 (2003), 3160-3167.

Giachelli C.M. , Bae N. , Almeida M. , Denhardt D.T. , Alpers C.E. , Schwartz S.M. , Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques, J Clin Invest 92 (1993), 1686-1696.

Gotoh M. , Sakamoto M. , Kanetaka K. , Chuuma M. , Hirohashi S. , Overexpression of osteopontin in hepatocellular carcinoma, Pathol Int 52 (2002), 19-24.

Greene F.L. , Page D.L. , Fleming I.D. , Fritz A. , Balch C.M. , Haller D.G. , Morrow M. , eds, AJCC cancer staging manual, 6^th ed, New York Springer-Verlag, (2002).

Jansen R.J. , Tan X.L. , Petersen G.M. , Gene-by-environment interactions in pancreatic cancer: implications for prevention, Yale J Biol Med 88 (2015), 115-126.

Kaleağası oğlu F. , Berger M.R. , SIBLINGs and SPARC families: their emerging roles in pancreatic cancer, World J Gastroenterol 20 (2014), 14747-14759.

Kim J.H. , Skates S.J. , Uede T. , Wong K.K. , Schorge J.O. , Feltmate C.M. , Berkowitz R.S. , Cramer D.W. , Mok S.C. , Osteopontin as a potential diagnostic biomarker for ovarian cancer, JAMA 287 (2002), 1671-1679.

Kodydkova J. , Vavrova L. , Stankova B. , Macasek J. , Krechler T. , Zak A. , Antioxidant status and oxidative stress markers in pancreatic cancer and chronic pancreatitis, Pancreas 42 (2013), 614-621.

Kolb A. , Kleeff J. , Guweidhi A. , Esposito I. , Giese N.A. , Adwan H. , Giese T. , Büchler M.W. , Berger M.R. , Friess H. , Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions, Cancer Biol Ther 4 (2005), 740-746.

Konieczna L. , Skokowski J. , Oledzka I. , Macur K. , Belka M. , Baczek T. , Struck W. , Markuszewski M. , The osteopontin tissue level as a breast cancer biomarker in females after mastectomy measured by the capillary gel electrophoresis technique, Comb Chem High Throughput Screen 16 (2013), 331-338.

Koopmann J. , Fedarko N.S. , Jain A. , Maitra A. , Iacobuzio-Donahue C. , Rahman A. , Hruban R.H. , Yeo C.J. , Goggins M. , Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma, Cancer Epidemiol Biomarkers Prev 13 (2004), 487-491.

Koopmann J. , Rosenzweig N.W. , Zhang Z. , Canto M.I. , Brown D.A. , Hunter M. , Yeo C. , Chan D.W. , Breit S.N. , Goggins M. , Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9, Clin Cancer Res 12 (2006), 442-446.

Krechler T. , Jachymova M. , Pavlikova M. , Vecka M. , Zeman M. , Krska Z. , Svestka T. , Zak A. , Polymorphism-23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study, Neoplasma 56 (2009), 26-32.

Krechler T. , Zeman M. , Vecka M. , Macasek J. , Jachymova M. , Zima T. , Zak A. , Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus, Neoplasma 58 (2011), 58-64.

Kuno N. , Kurimoto K. , Fukushima M. , Hayakawa T. , Shibata T. , Suzuki T. , Sakakibara A. , Katada N. , Nakano S. , Takayama T. et al., Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a propective study in multiinstitutions, Pancreas 9 (1994), 725-730.

Lazar M. , Sullivan J. , Chipitsyna G. , Gong Q. , Ng C.Y. , Salem A.F. , Aziz T. , Witkiewicz A. , Denhardt D.T. , Yeo C.J. , Arafat H.A. , Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells, J Gastrointest Surg, DOI 10.1007/s11605-010-1338-0.

Le Q.T. , Sutphin P.D. , Raychaudhuri S. , Yu S.C. , Terris D.J. , Lin H.S. , Lum B. , Pinto H.A. , Koong A.C. , Giaccia A.J. , Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas, Clin Cancer Res 9 (2003), 59-67.

Li J.-J. , Li H.-Y. , Gu F. , Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta analysis, Gent Test Mol Biomarkers 18(8) (2014), 580-586.

Lin Y. , Yagyu K. , Egawa N. , Ueno M. , Mori M. , Nakao H. , Ishii H. , Nakamura K. , Wakai K. , Hosono S. , Tamakoshi A. , Kikuchi S. , An overview of genetic polymorphisms and pancreatic cancer risk in molecular epidemiologic studies, J Epidemiol 21 (2011), 2-12.

Louhimo J. , Alfthan H. , Stenman U.H. , Haglund C. , Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer, Oncology 66 (2004), 126-131.

Lund S.A. , Giachelli C.M. , Scatena M. , The role of osteopontin in inflammatory processes, J Cell Commun Signal 3 (2009), 311-322.

Marsche G. , Saemann M.D. , Heinemann A. , Holzer M. , Inflammation alters HDL composition and function: implications for HDL-raising therapies, Pharmacol Ther 137 (2013), 341-351.

Matusan-Ilijas K. , Behrem S. , Jonjic N. , Zarkovic K. , Lucin K. , Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma, Pathol Oncol Res 14 (2008), 293-298.

Nakamachi T. , Nomiyama T. , Gizard F. , Heywood E.B. , Jones K.L. , Zhao Y. , Fuentes L. , Takebayashi K. , Aso Y. , Staels B. , Inukai T. , Bruemmer D. , PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes, Diabetes 56 (2007), 1662-1670.

Nakamura M. , Oka M. , Iizuka N. , Kawauchi S. , Gondo T. , Ueno T. , Tangoku A. , Osteopontin expression in chronic pancreatitis, Pancreas 25 (2002), 182-187.

Nolen B.M. , Brand R.E. , Prosser D. , Velikokhatnaya L. , Allen P.J. , Zeh H.J. , Grizzle W.E. , Lomakin A. , Lokshin A.E. , Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study, PLoS ONE 9(4) (2014), e94928. doi: 101371/journal.pone.0094928..

Osayi S.N. , Bloomston M. , Schmidt C.M. , Ellison E.C. , Muscarella P. , Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review, Biomed Res Int 2014 (2014), 468959.

Pan H.W. , Ou Y.H. , Peng S.Y. , Liu S.H. , Lai P.L. , Lee P.H. , Sheu J.C. , Chen C.L. , Hsu H.C. , Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma, Cancer 98 (2003), 119-127.

Patarca R. , Saavedra R.A. , Cantor H. , Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene, Crit Rev Immunol 13 (1993), 225-246.

Poruk K.E. , Firpo M.A. , Scaife C.L. , Adler D.G. , Emerson L.L. , Boucher K.M. , Mulvihill S.J. , Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma, Pancreas 42 (2013), 193-197.

Riker A. , Libutti S.K. , Bartlets D.L. , Advances in the early detection, diagnosis and staging of pancreatic cancer, Surg Oncol 6 (1997), 157-169.

Sarosiek K. , Jones E. , Chipitsyna G. , Al-Zoubi M. , Kang C. , Saxena S. , Gandhi A.V. , Sendiky J. , Yeo C.J. , Arafat H.A. , Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN, J Gastrointest Surg 19 (2015), 639-650.

Saxena S. , Gandhi A. , Lim P.W. , Relles D. , Sarosiek K. , Kang C. , Chipitsyna G. , Sendecki J. , Yeo C.J. , Arafat H.A. , RAN GTPase and Osteopontin in Pancreatic Cancer, Pancreat Disord Ther 3 (2013), 113.

Schneider A. , Löhr J.M. , Winter M.V. , The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classification of the disease, J Gastroenterol 42 (2007), 101-119.

Senger D.R. , Perruzzi C.A. , Papadopoulos A. , Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation, Anticancer Res 9 (1989), 1291-1299.

Shang S. , Plymoth A. , Ge S. , Feng Z. , Rosen H.R. , Sangrajrang S. , Hainaut P. , Marrero J.A. , Beretta L. , Identification of osteopontin as a novel marker for early hepatocellular carcinoma, Hepatology 55 (2012), 483-490.

Shijubo N. , Uede T. , Kon S. , Maeda M. , Segawa T. , Imada A. , Hirasawa M. , Abe S. , Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma, Am J Respir Crit Care Med 160 (1999), 1269-1273.

Siddiqui A.A. , Jones E. , Andrade D. , Shah A. , Kowalski T.E. , Loren D.E. , Chipitsyna G. , Arafat H.A. , Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma, J Gastroenterol Hepatol 29 (2014), 1321-1327.

Singhal H. , Bautista D.S. , Tonkin K.S. , O'Malley F.P. , Tuck A.B. , Chambers A.F. , Harris J.F. , Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival, Clin Cancer Res 3 (1997), 605-611.

Sodhi C. , Phadke S.A. , Batlle D. , Sahai A. , Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin, Am J Physiol Renal Surgery 146 (2009), 232-240.

Sullivan J. , Blair L. , Alnajar A. , Aziz T. , Ng C.Y. , Chipitsyna G. , Gong Q. , Witkiewicz A. , Weber G.F. , Denhardt D.T. , Yeo C.J. , Arafat H.A. , Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma, Physiol 280 (2009), F667-F674.

Takada H. , Nakazawa T. , Ohara H. , Ando T. , Hayashi K. , Naito I. , Okumura F. , Tanaka H. , Yamada T. , Takahashi S. , Joh T. , Role of osteopontin in calcification in autoimmune pancreatitis, Dig Dis Sci 54 (2009), 793-801.

Takemoto M. , Yokote K. , Nishimura M. , Shigematsu T. , Hasegawa T. , Kon S. , Uede T. , Matsumoto T. , Saito Y. , Mori S. , Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis, Arterioscler Thromb Vasc Biol 20 (2000), 624-628.

Thalmann G.N. , Sikes R.A. , Devoll R.E. , Kiefer J.A. , Markwalder R. , Klima I. , Farach-Carson C.M. , Studer U.E. , Chung L.W. , Osteopontin: possible role in prostate cancer progression, Clin Cancer Res 5 (1999), 2271-2277.

Thoms J.W. , Dal Pra A. , Anborgh P.H. , Christensen E. , Fleshner N. , Menard C. , Chadwick K. , Milosevic M. , Catton C. , Pintilie M. , Chambers A.F. , Bristow R.G. , Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response, Br J Cancer 107 (2012), 840-846.

Tuck A.B. , O'Malley F.P. , Singhal H. , Tonkin K.S. , Harris J.F. , Bautista D. , Chambers A.F. , Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas, Arch Pathol Lab Med 121 (1997), 578-584.

Tuck A.B. , O'Malley F.P. , Singhal H. , Harris J.F. , Tonkin K.S. , Kerkvliet N. , Saad Z. , Doig G.S. , Chambers A.F. , Osteopontin expression in a group of lymph node negative breast cancer patients, Int J Cancer 79 (1998), 502-508.

Tuck A.B. , Arsenault D.M. , O'Malley F.P. , Hota C. , Ling M.C. , Wilson S.M. , Chambers A.F. , Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells, Oncogene 18 (1999), 4237-4246.

Tuck A.B. , Chambers A.F. , Allan A.L. , Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management, J Cell Biochem 102 (2007), 859-868.

Ue T. , Yokozaki H. , Kitadai Y. , Yamamoto S. , Yasui W. , Ishikawa T. , Tahara E. , Co-expression of osteopontin and CD44v9 in gastric cancer, Int J Cancer 79 (1998), 127-132.

Yachida S. , Jones S. , Bozic I. , Antal T. , Leary R. et al., Distant metastasis occurs late during the genetic evolution of pancreatic cancer, Nature 467 (2010), 1114-1117.

Yamaguchi H. , Igarashi M. , Hirata A. , Tsuchiya H. , Sugiyama K. , Morita Y. , Jimbu Y. , Ohnuma H. , Daimon M. , Tominaga M. , Kato T. , Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients, Endocr J 51 (2004), 499-504.

Yan X. , Sano M. , Lu L. , Wang W. , Zhang Q. , Zhang R. , Wang L. , Chen Q. , Fukuda K. , Shen W. , Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus, Cardiovasc Diabetol 9 (2010), 70.

Vavrova L. , Rychlikova J. , Mrackova M. , Novakova O. , Zak A. , Novak F. , Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin, Clin Exp Med (Sep 28 2015). [Epub ahead of print].

Vestergaard E.M. , Hein H.O. , Meyer H. , Grunnet N. , Jørgensen J. , Wolf H. , Ørntoft T.F. , Reference values and biological variation for tumor marker CA 19-9 in serum for different lewis and secretor genotypes and evaluation of secretor and lewis genotyping in a caucasian population, Clin Chem 45 (1999), 54-61.

Wai P.Y. , Kuo P.C. , The role of osteopontin in tumor metastasis, J Surg Res 121 (2004), 228-241.

Weber G.F. , Ashkar S. , Glimcher M.J. , Cantor H. , Receptor-ligand interaction between CD44 and osteopontin (Eta-1), Science 271 (1996), 509-512.

Weber G.F. , The metastasis gene osteopontin: a candidate target for cancer therapy, Biochim Biophys Acta 1552 (2001), 61-85.

Zhou C. , Zhou H.J. , Zhang X.F. , Lou L.L. , Ye Q.H. , Zheng Y. , Wang J. , Zhu H.T. , Dong Q.Z. , Jia H.L. , Zhu W.W. , Guo L. , Zhao Y. , Gao D.M. , Qin L.X. , Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma, Ann Surg Oncol 20 (2013), 929-937.